DEPTOR (DEP Domain Containing MTOR Interacting Protein), encoded by the DEPTOR gene (also known as DEPDC1), is an endogenous inhibitor of both mechanistic target of rapamycin complex 1 (mTORC1) and mTORC2. Discovered in 2009, DEPTOR represents a unique node in the mTOR signaling network, functioning as a physiological brake on cell growth and metabolism while paradoxically promoting cell survival in certain cancer contexts.
The DEPTOR protein contains N-terminal DEP (Dishevelled, Egl-10, Pleckstrin) domains and a C-terminal PDZ (Postsynaptic density 95, Discs large, Zonula occludens-1) domain, which mediate its interactions with mTOR and other signaling proteins. Under conditions of nutrient sufficiency, DEPTOR is phosphorylated by mTORC1 and subsequently degraded, releasing the brake on mTOR activity. This dynamic regulation allows cells to respond rapidly to changing environmental conditions.
In the central nervous system, DEPTOR is expressed in neurons and glia, where it plays important roles in regulating autophagy, synaptic plasticity, and cellular stress responses. Dysregulated DEPTOR-mTOR signaling has been implicated in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions, making this pathway a therapeutic target of interest.
Gene Symbol: DEPTOR
Alternative Names: DEP Domain-containing protein 1, DEPDC1
Chromosomal Location: 8q24.3
NCBI Gene ID: 64798
OMIM: 614619
Ensembl ID: ENSG00000155792
UniProt ID: Q9Y282
Protein Length: 409 amino acids
Gene Family: DEP domain-containing proteins
Associated Diseases: Multiple myeloma, Endometrial cancer, Thyroid carcinoma, Alzheimer's disease, Parkinson's disease
¶ Structure and Molecular Mechanism
The DEPTOR gene spans approximately 40 kb on chromosome 8q24.3 and consists of 11 exons. The coding sequence encodes a protein of 409 amino acids with a molecular weight of approximately 46 kDa. Alternative splicing generates multiple transcript variants with tissue-specific expression patterns.
¶ Protein Domain Architecture
DEPTOR contains several distinctive functional domains:
¶ N-terminal DEP Domains (Residues 1-200)
The N-terminal region contains two DEP domains:
- DEP domain 1 (D1): Residues 1-100
- DEP domain 2 (D2): Residues 100-200
These domains are characteristic of the DEP domain family and mediate:
- Protein-protein interactions
- Membrane association (some DEP domains bind phospholipids)
- Interaction with the mTOR FAT domain
¶ C-terminal PDZ Domain (Residues 300-380)
The PDZ domain at the C-terminus:
- Recognizes C-terminal peptide motifs
- Mediates scaffold formation
- Participates in signaling complex assembly
- Binds to mTOR and other partners
¶ Interdomain Regions
The regions between domains contain:
- Phosphorylation sites (Ser, Thr, Tyr)
- degron sequences for protein degradation
- Intrinsically disordered regions for regulatory interactions
DEPTOR binds to the FAT (FKBP12-rapamycin associated protein (FRB)-Associated Translocating) domain of mTOR through its DEP domains. This binding sterically inhibits kinase activity:
mTORC1 Inhibition:
- DEPTOR binds to FRB domain
- Prevents substrate access to kinase active site
- Inhibits S6K1 and 4E-BP1 phosphorylation
mTORC2 Inhibition:
- DEPTOR binds to FAT domain
- Blocks AKT phosphorylation at T450
- Reduces AKT signaling output
DEPTOR levels are tightly regulated:
- mTORC1 phosphorylates DEPTOR at multiple sites
- Phosphorylation creates degron for SCF-βTrCP recognition
- Polyubiquitination targets DEPTOR for proteasomal degradation
- Nutrient withdrawal stabilizes DEPTOR
- mTORC1-S6K1 axis suppresses DEPTOR transcription
- ATF4 and other stress-responsive transcription factors upregulate DEPTOR
- Hypoxia induces DEPTOR expression via HIF-1α
- Ubiquitination: Multiple lysine residues modified
- Sumoylation: Affects protein stability
- Acetylation: Modulates protein-protein interactions
DEPTOR is a central regulator of mTOR signaling:
When bound to mTORC1, DEPTOR:
- Inhibits kinase activity toward S6K1 and 4E-BP1
- Prevents phosphorylation of ribosomal protein S6
- Blocks cap-dependent translation
- Reduces cell growth and proliferation
DEPTOR also inhibits mTORC2:
- Prevents AKT phosphorylation at T450
- Reduces AKT membrane localization and activation
- Impairs AKT downstream signaling
- Affects cell survival and metabolism
Through mTOR inhibition, DEPTOR promotes autophagy:
mTORC1 inhibition releases autophagy inhibition:
- Ulk1 complex activation
- VPS34 complex stimulation
- Autophagosome nucleation
- LC3 lipidation and autophagosome formation
DEPTOR enhances autophagic flux:
- Increases lysosomal biogenesis
- Enhances cargo recruitment
- Promotes autophagosome-lysosome fusion
DEPTOR affects multiple metabolic pathways:
- Inhibits SREBP-dependent lipogenesis
- Reduces triglyceride synthesis
- Modulates cholesterol homeostasis
- Reduces AKT-mediated glucose uptake
- Decreases glycolytic rate
- Affects insulin signaling
- Modulates mitochondrial dynamics
- Affects oxidative phosphorylation
- Regulates mitochondrial biogenesis
¶ Cell Survival and Death
DEPTOR has complex effects on cell survival:
- Inhibition of mTORC2-AKT promotes apoptosis in some contexts
- However, in cancer cells, DEPTOR can promote survival through:
- Maintained AKT S473 phosphorylation (incomplete inhibition)
- Autophagy activation
- Metabolic reprogramming
- In certain contexts, DEPTOR promotes apoptosis
- mTORC1 inhibition reduces cell proliferation
- Autophagy过度激活 can lead to cell death
DEPTOR is widely expressed with variable levels:
| Tissue |
Expression Level |
Notes |
| Brain |
Highest |
Cortex, cerebellum, hippocampus |
| Heart |
High |
Cardiac muscle function |
| Skeletal Muscle |
High |
Metabolic demand |
| Kidney |
Moderate |
Excretory function |
| Liver |
Moderate |
Metabolic activity |
| Lung |
Moderate |
Barrier function |
| Adipose |
Moderate |
Metabolic regulation |
| Immune Cells |
Variable |
Activation-dependent |
In the central nervous system, DEPTOR shows:
Regional Distribution:
- Highest in cerebral cortex (layer 5 pyramidal neurons)
- Strong expression in hippocampus (CA1-CA3, dentate gyrus)
- Purkinje cells in cerebellum
- Substantia nigra dopaminergic neurons
- Lower expression in white matter
Cellular Localization:
- Neurons: High expression in soma and dendrites
- Glia: Moderate expression in astrocytes and microglia
- Subcellular: Cytoplasmic and membrane-associated
Developmental Expression:
- Embryonic brain: Moderate expression
- Postnatal: Increasing expression
- Adult: High maintenance in regions of synaptic plasticity
¶ Cellular and Subcellular Distribution
DEPTOR localizes to:
- Cytoplasm: Primary location
- Endoplasmic reticulum: Via PDZ domain interactions
- Golgi apparatus: Partial localization
- Lysosomes: Upon autophagy activation
- Nucleus: Lower levels (non-canonical functions)
DEPTOR has several connections to Alzheimer's disease:
- mTOR hyperactivation in AD brain
- Reduced DEPTOR expression in AD
- Contributes to translation dysregulation
- Affects synaptic plasticity
- Impaired autophagic flux in AD
- Reduced DEPTOR limits autophagy activation
- Accumulation of protein aggregates
- Failed clearance of Aβ and tau
- mTOR-mediated synaptic plasticity deficits
- Altered spine morphology
- Memory consolidation impairment
- Enhancing DEPTOR could restore mTOR balance
- Autophagy activation via DEPTOR
- Reducing Aβ and tau pathology
DEPTOR connections to Parkinson's disease:
- Altered mTOR activity in PD models
- DEPTOR expression changes
- Affects dopaminergic neuron survival
¶ Autophagy and α-Synuclein
- Impaired autophagic clearance of α-synuclein
- DEPTOR enhancement could promote clearance
- Reduced protein aggregation
- DEPTOR affects mitochondrial dynamics
- PINK1/PARKIN pathway interactions
- Altered mitophagy in PD
- Neuroprotective effects of DEPTOR
- Autophagy enhancement
- Alpha-synuclein clearance promotion
- mTOR dysregulation
- Autophagy impairment
- Mutant huntingtin effects
- Altered mTOR signaling
- Autophagy defects
- Motor neuron vulnerability
- Demyelination processes
- Oligodendrocyte function
- Neuroinflammation modulation
DEPTOR has paradoxical roles in cancer:
DEPTOR is elevated in:
- Multiple myeloma
- Endometrial cancer
- Thyroid carcinoma
- Certain lymphomas
- Renal cell carcinoma
Despite being an mTOR inhibitor, DEPTOR promotes cancer:
- Incomplete mTORC2 inhibition
- Maintains AKT S473 phosphorylation
- Autophagy promotes survival
- Metabolic reprogramming
Targeting DEPTOR in cancer:
- mTOR inhibitors: Overcome DEPTOR-mediated resistance
- Proteasome inhibitors: Induce DEPTOR accumulation
- Combination strategies
| Complex |
Interaction |
Effect |
| mTORC1 |
Direct binding |
Inhibits kinase activity |
| mTORC2 |
Direct binding |
Partial inhibition |
| Raptor |
Through mTOR |
Regulatory |
| Rictor |
Through mTOR |
Regulatory |
DEPTOR affects multiple downstream pathways:
mTORC1 Outputs:
- S6K1/2 → Growth, translation
- 4E-BP1 → Translation initiation
- ULK1 → Autophagy (inhibition lifted)
mTORC2 Outputs:
- AKT → Survival, metabolism
- PKCα → Cell polarity
- SGK1 → Ion transport
DEPTOR interacts with:
- SCF-βTrCP: For degradation
- PDZ domain proteins: Scaffold functions
- Transcription factors: Transcriptional regulation
Targeting the DEPTOR-mTOR axis:
- Rapamycin and analogs (rapalogs)
- ATP-competitive inhibitors
- Dual mTORC1/mTORC2 inhibitors
- Autophagy enhancers (rapamycin, carbamazepine)
- Autophagy inhibitors (chloroquine) in cancer
- mTOR inhibitors + autophagy modulators
- Targeted therapy combinations
DEPTOR-Targeting Approaches:
- Gene therapy to increase DEPTOR expression
- Small molecules stabilizing DEPTOR
- Peptide inhibitors of mTOR-DEPTOR interaction
Neurodegeneration-Specific:
- Brain-penetrant mTOR inhibitors
- Autophagy-activating compounds
- Neuroprotective strategies
Selectivity:
- mTOR has multiple functions
- Systemic vs. CNS effects
- Cell-type specificity
Safety:
- Immunosuppression risk
- Metabolic side effects
- Tumor-promoting potential
Delivery:
- Detailed structural mechanism of DEPTOR inhibition
- Cell-type specific functions in vivo
- Disease-modifying mechanisms
- Biomarkers for therapeutic response
- Structural studies of DEPTOR-mTOR complex
- Brain-penetrant mTOR modulators
- Autophagy enhancers for neurodegeneration
- Gene therapy approaches
- Combination therapy strategies